The ␣␤ TCR is part of a large protein complex composed of the CD3-␥, ␦, ⑀, and polypeptide chains. These proteins contain signaling motifs called immune receptor tyrosine-based activation motifs (ITAMs) with the consensus sequence YXX(L/I)X 6-8 YXX (L/I) (1, 2) . Upon phosphorylation, this motif is sufficient to transduce signals from the TCR. The CD3-␥, ␦ and ⑀ chains contain one ITAM, and contains three ITAMs. The multiple ITAMs are believed to amplify signals from the TCR (3) . Another function of the TCR/CD3 complex could be to qualitative evaluate ligands of the ␣␤ TCR upon cross-linking (4, 5) .
To further examine the function of ITAM tyrosines in CD3-⑀, we constructed chimeric molecules containing the extracellular and transmembrane domains of human CD8␣ and the cytoplasmic domain of mouse CD3-⑀ (designated CD8-⑀). Similar constructs bearing mutations at either one or both ITAM tyrosine residues were generated (designated Y170F, Y181F, and Y170F/ Y181F). Analysis of signaling by these chimeras indicates that ITAM tyrosines are functionally distinct. The data support a model in which the sequential and coordinated phosphorylation of CD3-⑀-ITAM tyrosines provides to CD3-⑀ the potential to interact with multiple downstream effectors and signaling pathways.
MATERIALS AND METHODS
Cells. Jurkat human T cells (ATCC) were used. Cells were grown in RPMI 1640 (Life Technologies, Inc.) with 10% FCS (BioWhittaker), penicillin, streptomycin and 2 mM glutamine. Jurkat T cell lines expressing wild-type CD8-⑀ chimeric proteins have been previously described (6) . Jurkat cells expressing CD8-⑀ chimeric molecules with phenyalanine substitution at the N-terminal CD3-⑀-ITAM tyrosine (Y170F), C-terminal ITAM tyrosine (Y181F), or both ITAM tyrosines (Y170F/Y181F) were a gift from Dr. Dexian Zheng (Institute of Basic Medical Sciences, Beijing, China). Polyclonal lines were used for experimentation rather than clones to avoid potential artifacts resulting from clonal variation. Cells were periodically screened for surface expression of the chimeras by staining with anti-CD8 (OKT8) antibody and fluorescein conjugated goat antimouse antibody and analyzed by flow cytometry. COS-7 monkey kidney epithelial cells were cultured in Dulbecco's modified Eagle medium with 4500 mg/L D-glucose, 10% FCS, penicillin, streptomycin, glutamine, sodium pyruvate, and 10 mM Hepes (Life Technologies, Inc.).
Antibodies. Anti-phosphotyrosine horseradish peroxidase conjugate RC20 (E120H, Transduction Laboratories); anti-p85 PI 3-kinase subunit polyclonal antibody (Santa Cruz, CA); anti-Shc pAb (Transduction Laboratories); anti human Lck (NT, peptide based upon amino acid residues 22-51) rabbit polyclonal antibody (Upstate Biotechnology, Inc.); anti-ZAP70 polyclonal antibody Zap-4 (generously donated by Dr. Steven C. Ley, Medical Research Council, London); affinity-purified anti CD3-⑀ anti-peptide polyclonal antibody (Dako); affinity-purified OKT3 mAb and OKT8 mAb were obtained from tissue culture supernatant of OKT3 and OKT8 hybridomas acquired from ATCC.
CD8-⑀ chimeric molecules and other cDNA constructs. CD8-⑀ is a chimeric protein consisting of the entire human CD8␣ extracellular and transmembrane domains fused to mouse CD3-⑀ cytoplasmic domain, or to mutated CD3-⑀ containing either one or two tyrosine to phenylalanine mutations within the CD3-⑀-ITAM (6) . Lck and ZAP-70 cDNAs were generously donated by Drs. C. Rudd (DanaFarber Cancer Institute, Boston, MA), and Andrey C. Shaw (Washington University School of Medicine, St. Louis, MO), respectively.
Peptide synthesis procedure. Peptides were synthesized as a C-terminal amide form by solid-phase synthesis, using standard Fmoc chemistry on an automated multiple peptide synthesizer AMS 422 (Abimed, 422, Langelfeld, Germany). Peptides were chemically synthesized with an additional N-terminal lysine for coupling to Affi-Gel 10 matrix (Bio-Rad), and a pair of glycines at positions ϩ2 and ϩ3 to provide a spacer to minimize steric interference from the solid support (7). Coupling efficiency was monitored by determining the degree of binding of anti-peptide and anti-phosphotyrosine antibodies to the peptide affinity matrices as described (6, 8) . Trk-ApY490 peptide represented the binding site for PTB-containing proteins present in Trk-A (9 -11). pY170 represented the sequence PVPNPDY PO4 EPIR of mouse CD3-⑀ (residues 164 -174) that contains both the SH2-binding site (Y PO4 EPI) and a putative PTB-binding site (VPNPDY PO4 ; hydrophobic-X-N-P-X-Y PO4 ) (12) (13) (14) . In peptide Y170F, Y 170 was replaced by phenylalanine and therefore represented the unphosphorylated version of peptide pY170. In I173D, isoleucine (residue 173) was replaced by aspartic acid. I173D substitution was made to eliminate the SH2-binding capacity of pY170, and to render it more similar to the Trk-A peptide. pY181 peptide comprised the tyrosine phosphorylated C-terminal YSGL segment of CD3-⑀-ITAM (residues 176 -185). 2pITAM peptide represented the whole CD3-⑀-ITAM phosphorylated on both tyrosines (residues 169 -185), and PLC-␥1 represented an unphosphorylated peptide close to the C-terminus of human PLC-␥1 (residues 1268 -1287).
Affinity binding assay. NP-40 Jurkat cell lysates were precleared with BSA-Affi-Gel 10 before incubation with CD3-⑀ peptide affinity matrices for 1 h at 4°C. Beads were then washed twice in solution A (0.5% NP-40, 150 mM NaCl, 20 mM Hepes, pH 7.6, and 100 M sodium orthovanadate), twice in solution B (0.1% NP-40, 150 mM NaCl, 0.5 M LiCl, 20 mM Hepes, pH 7.6, and 100 M sodium orthovanadate) and once in solution C (150 mM NaCl, and 20 mM Hepes, pH 7.6).
Cell stimulation, immunoprecipitation, and Western blotting.
Jurkat CD8-⑀ cells and mutants were stimulated, immunoprecipitated and Western blotted as described in detail elsewhere (6) . Densitometric analysis was performed on a Macintosh computer using the public domain NIH Image 1.6 program (developed at the U.S. National Institutes of Health and available on the Internet at http:// rsb.info.nih.gov/nih-image/). DNA transfections. COS-7 cells were transfected with 1 g of expression vectors, containing the appropriate cDNA insert, by the FuGENE 6 transfection reagent (Roche Diagnostics, SL, Barcelona, Spain), according to the manufacturer's instructions. Cells were harvested 48 h after transfection and lysed in NP-40 lysis buffer as described elsewhere (6) . Aliquots of these lysates were subjected to immunoblotting with Abs to Lck, ZAP-70 and CD3-⑀ to confirm protein expression. In transfected cells surface expression of the CD8-⑀ chimera was analyzed by flow cytometry with OKT8 antibody.
RESULTS

In T Cells, Receptor-Mediated Phosphorylation of the N-Terminal and the C-Terminal CD3-⑀-ITAM Tyrosines Is Differentially Regulated
A chimeric protein in which the cytoplasmic tail of human CD8␣ was replaced by the cytoplasmic tail of murine CD3-⑀ is functionally active in transfected Jurkat T cells. Thus, incubation of these cells, termed CD8-⑀ wt, with anti-CD8 induces PTK and PI 3-K activation (6). Here we have transfected Jurkat T cells with cDNAs encoding three mutants of the CD8-⑀ wt chimeric protein. The chimera Y170F with a phenylalanine substitution at the N-terminal CD3-⑀-ITAM tyrosine retained Y 181 for phosphorylation. The chimera Y181F, with the C-terminal CD3-⑀-ITAM tyrosine mutated retained Y 170 for phosphorylation. Y170F/Y181F with no tyrosines available for phosphorylation was used as a control. Positive cell lines were identified by FACS analysis with an anti-CD8 mAb. In addition, cells were examined for surface expression of the endogenous TCR/CD3 complex and CD45 (data not shown). Only cell lines with comparable surface expression of these three parameters were further analyzed.
Since ITAM tyrosines are critical for ITAM-mediated signaling functions, we assessed tyrosyl phosphorylation of the chimeras themselves. To this end, the tyrosine phosphorylation state of the CD8-⑀ chimeric proteins were examined upon cell stimulation with anti-CD8 alone, and compared with that observed in unstimulated cells, or stimulated with the combination of pervanadate and OKT8. Pretreatment of cells with inhibitors of PTPases, mostly phenylarsine oxide or pervanadate, has been shown to enhance recoveries of phosphotyrosine, and has facilitated the detection of phosphoproteins involved in TCR-mediated signal transduction (15) . In CD8-⑀ wt and Y181F cells tyrosine phosphorylation of both chimeric receptors significantly increased with anti-CD8 mAb stimulation alone ( 
Tyrosine Phosphorylation of CD8-⑀ Chimeras by Lck and ZAP-70 in COS Cells
A previously described reconstitution system was used (6, 16) to determine whether Lck, or ZAP-70 were capable of directly phosphorylate the Y170F and Y181F chimeras in vivo. In this system, COS-7 cells were transiently transfected with each chimeric receptor cDNA alone, or co-transfected with Lck, or ZAP-70 alone, or the combination of Lck and ZAP-70 cDNAs. After 48 h, the chimeric proteins were immunoprecipitated with the anti-CD8 mAb OKT8 and analyzed by SDS-PAGE and Western blotting with anti-phosphotyrosine mAb (Fig. 1E ). Lck expression resulted in a marked increase in the level of tyrosine phosphorylation of the three chimeric proteins CD8-⑀ wt, Y170F, and Y181F (Fig. 1E , upper panel, lanes 2, 6, and 10), but not of the double mutant Y170F/Y181F (lane 14). As expected the extent of phosphorylation of Y170F and Y181F mutants was lower than that in CD8-⑀ wt, since they have a single tyrosine available for phosphorylation, whereas the CD8-⑀ wt chimera has two. In contrast, expression of ZAP-70 alone only increased the level of tyrosine phosphorylation of the CD8-⑀ wt chimera (Fig. 1E, upper panel, lane 3) , and very little of the Y170F and YY181F chimeras (Fig. 1E , upper panel, lanes 7, and 11, respectively). However, the extent of CD8-⑀ wt tyrosine phosphorylation by ZAP-70 was significantly lower than that by Lck (compare lane 3 vs lane 2). Coexpression of Lck and ZAP-70 did not result in further increases in chimeric protein tyrosine phosphorylation compared with that in cells expressing Lck alone (Fig. 1E, upper panel, lanes 4, 8, and 12) . Therefore, in contrast with what it was observed in T cells, in Lck-transfected COS cells the Y170F chimera was significantly tyrosine phosphorylated. These results demonstrate that, both Y170F and Y181F chimeric proteins could be efficiently phosphorylated by Lck in vivo. Therefore, the N-terminal YEPI and C-terminal YSGL segments within CD3-⑀-ITAM are good substrates for this PTK. In contrast, only CD8-⑀ wt chimera seems to be a relatively good substrate for ZAP-70 PTK.
Distinct Recruitment of Signaling Molecules by Monophosphorylated or Diphosphorylated CD8-⑀ Chimeric Proteins in Vivo
CD3-ITAM phosphotyrosine residues mediate the binding of signaling molecules such as ZAP-70 through 4, 7, 8, 11, 12, 15, and 16 ). Forty-eight hours after transfections, cells were harvested and lysed with 1% NP-40 lysis buffer. Anti-CD8␣ mAb OKT8 immunoprecipitates were subjected to SDS-PAGE followed by Western blotting and incubation with the antiphosphotyrosine mAb RC20-HRP (upper panels). Blots were then stripped and reprobed with CD3-⑀ specific antibody (lower panels). Position of tyrosine phosphorylated chimeras [Ch(P)], and unphosphorylated chimeras (Ch) are indicated to the right of the corresponding panel. In the upper panels of C and D, the position of the light chain (L) of the antibody used for immunoprecipitation is also indicated.
interactions with SH2 domains (1). To determine whether phosphorylation of the CD8-⑀ chimeras is necessary and sufficient to recruit signaling molecules in transfected-Jurkat T cells, cells were pulsed for 2 min with 100 M pervanadate before stimulation with the anti-CD8 mAb OKT8 for 5 min. Following stimulation cells were lysed, the CD8-⑀ chimeric proteins were immunoprecipitated, and tyrosine phosphorylation of the chimeras was analyzed. As shown in Fig. 2 , while Y170F chimera was barely tyrosine phosphorylated upon stimulation with the combination of pervanadate and OKT8 mAb (Fig. 2A, lane 5) , both the CD8-⑀, and the Y181F chimeras resulted significantly phosphorylated ( Fig. 2A, lanes 3 and 7, respectively) . As expected, no tyrosine phosphorylation of Y170F/Y181F chimera was detected (Fig. 2A, lane 9) .
The Y181F chimera preferentially associated with a 56-to 60-kDa phosphorylated protein (Fig. 2A, lane 7) that was confirmed to be Lck by Western blotting (Fig.  2D, lane 7) . In addition, Y181F, and to a lesser extent CD8-⑀ wt, also showed a significant association with p85 PI 3-K upon receptor cross-linking (Fig. 2B, lanes  7 and 3, respectively) . In contrast, CD8-⑀ wt preferentially associated with a 70 kDa phosphorylated protein (Fig. 2A, lane 3) , which was confirmed to be ZAP-70 by parallel Western blotting analysis with a ZAP-70 specific antiserum (Fig. 2C, lane 3) . Note that despite the amount of immunoprecipitated Y181F chimera was higher than that of CD8-⑀ wt (Fig. 2E) , very little amount of ZAP-70 was co-immunoprecipitated with Y181F. Moreover, neither Y170F nor Y170F/Y181F chimeras did show any preferential binding to any of these proteins (Figs. 2B-2D, lanes 5 and 9) . This distinct pattern of association was still detectable when the data were normalized by the amount of immunoprecipitated chimeric protein (data shown below each panel), or with 2-fold less number of cells (data not shown). Moreover, in Jurkat T cells, fully stimulated with an anti-CD3 mAb OKT3 plus pervanadate, CD3-⑀ resulted tyrosine phosphorylated and associated with ZAP-70, and to a lesser extent with p85 PI 3-kinase, but not with Lck (data not shown). These results are consistent with the data on CD8-⑀ wt cells.
Association of Lck with CD8-⑀ Chimeric Receptors Is Sensitive to Treatment with the Raft-Disrupting Octylglucoside
To test for the involvement of rafts in directing the interactions between Lck and monophosphorylated Y181F, we analyzed the sensitivity of co-immunoprecipitation of Lck with the CD8-⑀ chimeras to treatment with octylglucoside (ODG), agent that disrupt raft stability (17) (18) (19) . To this end, COS-7 cells were transiently transfected with CD8-⑀ wt or Y181F cDNAs, and cotransfected with Lck and ZAP-70 cDNAs. After 48 h, cells were lysed in 1% NP-40 lysis buffer alone, or in 1% NP-40 containing 60 mM ODG. Then the chimeric proteins were immunoprecipitated with the anti-CD8 mAb OKT8 and analyzed by SDS-PAGE and Western blotting with anti-phosphotyrosine mAb. As shown in Fig. 3C , the association of Lck with CD8-⑀ wt, or Y181F was almost entirely abolished by addition of ODG to the NP-40 lysis buffer (lanes 2 and 3 vs lanes 4 and 5). Likewise, the association of ZAP-70 with the Y181F chimera was significantly reduced (Fig. 3B , lane 3 vs lane 5), whereas association of ZAP-70 with CD8-⑀ wt was very similar to that in NP-40 lysis buffer (Fig.  3B, lane 2 vs lane 4) . These results suggest that the stability and extent of the ZAP-70/CD8-⑀ wt interaction is largely independent on the integrity of rafts, whereas the Lck/Y181F interaction requires rafts for stabilizing SH2 phosphotyrosine interactions. The data also confirm and extend the Jurkat experiments showing the preferential association of ZAP-70 and Lck to tyrosine phosphorylated CD8-⑀ wt and Y181F chimeras, respectively.
N-Terminal and C-Terminal Phosphotyrosine Motifs within the CD3-⑀ ITAM Bind Distinct Effector Molecules in Vitro
To examine whether segments representing partially phosphorylated CD3-⑀ species could specifically bind SH2-or PTB-containing proteins, we constructed chemically synthesized peptides representing the individual CD3-⑀-ITAM tyrosines. The peptides were coupled to Affi-Gel 10 matrix as described under Materials and Methods. Equivalent amounts of each of the CD3-⑀-ITAM peptides coupled to Affi-Gel 10 were used to precipitate proteins from Nonidet P-40 lysates of Jurkat T cells. Bound proteins were eluted and resolved by SDS-polyacrylamide gel electrophoresis, transferred electrophoretically to PVDF membranes, and subjected to Western blot analysis with antibodies to p85 PI 3-K, Shc, Lck, and ZAP-70. As shown in Fig. 4A , p85 PI 3-K, Shc and Lck did bind very efficiently to tyrosinephosphorylated pY170 peptide (lane 4), and very little to the other phosphorylated peptides. The only exception to this pattern was Shc that also bound to Trk-A peptide (Fig. 4A, lane 3) , that represented the canonical PTB-binding site. In contrast, ZAP-70 associated to the other single tyrosine-phosphorylated peptide, pY181, or to doubly phosphorylated 2pITAM peptide but not to pY170 (Fig. 4A, lanes 7 and 8) . As expected, not a single protein analyzed bound to unphosphorylated Y170F peptide (Fig. 4A, lane 5) . Of note is that Shc bound very little to phosphorylated I173D peptide, which contains a single amino acid substitution at the position ϩ3 respective to the phosphorylated tyrosine in pY170 peptide (Fig. 4A, lane 6) . These data suggested that Shc binds to the tyrosine phosphorylated N-terminal YEPI segment within the CD3-⑀-ITAM via its SH2 domain and not through its putative PTB domain.
To examine further the interactions of phosphorylated CD3-⑀-ITAM peptides with these signaling molecules, we precipitated proteins from Jurkat T cell lysates with a titration of concentrations of the N-terminal and C-terminal CD3-⑀-ITAM peptides (750 to 37.5 nM). The data in Fig. 4B show that Lck, Shc and p85 PI 3-K bound to pY170 peptide with similar efficiency regardless the concentration of the peptide used (Fig. 4B, lanes 3-5) . In contrast, ZAP-70 did not bind to this peptide at any concentration tested, whereas it associated very efficiently with pY181 peptide (compare in Fig. 4B, lanes 3-5 vs lanes 6 -8) . p85 PI 3-K and Shc did also bind to pY181 but with much less efficiency than ZAP-70, even at the higher peptide concentration used, and Lck did not bind to pY181 at all (Fig. 4B, lanes 6 -8) . Overall, these results confirm and extend the in vivo data on the distinct binding capacity of each tyrosine within CD3-⑀-ITAM. Thus, the N-terminal Y PO4 EPI is sufficient by itself for the stable binding of Lck, p85 PI 3-kinase, and Shc, whereas the C-terminal Y PO4 SGL is enough for stable association with ZAP-70.
DISCUSSION
By using the mouse CD3-⑀ cytoplasmic tail expressed independently as fused chimeric receptor with the human CD8␣ extracellular and transmembrane domains, we have shown that the N-terminal tyrosine, Y 170 , appears to be the initial and preferred site of phosphorylation of the CD3-⑀ polypeptide chain, since phenylalanine substitution at this position effectively abolishes all inducible tyrosine phosphorylation of the receptor and its association with p85 PI 3-K, Lck, or ZAP-70. In contrast, mutating the C-terminal tyrosine, Y 181 , has a distinct effect on phosphorylation and binding of associated effector or adapter proteins. Phosphorylation of the chimeric receptor itself is readily detected, as well as its preferential association with p85 PI 3-K and Lck. The weak induction of Y170F tyrosine phosphorylation was unexpected since it has been shown that pervanadate treatment, not only inhibits PTPase activity, but also stimulates catalytic activity of both Fyn and Lck PTKs (20) . Therefore, these results suggest that Y 170 might be a better substrate than Y 181 for the PTK responsible for the phosphorylation of the CD3-⑀-ITAM.
The Lck/CD3-⑀ phosphotyrosine interaction described here has distinct features to those described for Fyn/CD3-⑀ (21). It is restricted to the N-terminal YEPI segment within the CD3-⑀-ITAM. It is relatively tight as it is detectable in NP-40-based lysis buffer, and fulfills similar requirements for binding of Lck SH2 domain to high affinity phosphorylated ligand peptides (22) . However, similarly to the Fyn/CD3-interaction (23), Lck/CD3-⑀ interaction is sensitive to octylglucoside, agent that disrupt Lck association with membrane rafts (19) . Accumulation of Lck and CD3-⑀ in rafts may increase the local concentration of both proteins and stabilize their association. We speculate that Y 170 has an additional advantage over Y 181 to be phosphorylated by Lck because its proximity to a prolinerich region, which may interact with the SH3 domain of Lck. This interaction may release Lck from negative regulation by its own SH3 domain (24, 25) (26 -28) . According with this model, phosphorylation of one optimal site on the substrate by a PTK could allow binding of this kinase through its own SH2 domain to the target protein, thus enhancing phosphorylation of other less-optimal sites on the same substrate.
Alternatively, this difference might be that phosphorylation of Y 181 may occur in Y170F Jurkat T cells but is rapidly and selectively dephosphorylated by tyrosine phosphatases. Thus, PTPase inhibition by pervanadate treatment seems to be effective only with CD8-⑀ wt and Y181F cells, but not with Y70F cells. This could be indicative either of the presence of a PTPase specific for the Y181 residue, which its enzymatic activity is not sensitive to pervanadate treatment, or that phosphorylated Y 170 is better protected from dephosphorylation than Y 181 residue. This could be accomplished by specific binding of an SH2-containing protein as Lck to phosphorylated Y 170 , as it occurs for the high-affinity binding site for the SH2 domains of PLC-␥ in the EGF receptor (29) . To note is that in unstimulated COS cells, which do not express the PTPase CD45, both Y170F and Y181F chimeric receptors result tyrosine phosphorylated when cotransfected with Lck, but not with ZAP-70. The different behavior of these PTKs, despite the fact that both were overexpressed with the chimeras, indicates the validity of the system for this type of analysis and strongly suggest that in T cells phosphorylation of the N-terminal and the C-terminal CD3-⑀-ITAM tyrosines is differentially regulated. This could be indicative that there is a functional difference between the N-terminal and the C-terminal YXXL/I segment within a single CD3-⑀-ITAM.
The interaction reported here between phosphorylated Y 170 within the CD3-⑀-ITAM and Lck has important general implications for the relationship between nonreceptor tyrosine kinases and their substrates. We show in COS cells that specific phosphorylation of Y170F and Y181F chimeras by Lck, but not by ZAP-70, can be induced in the cell by high concentration of the two proteins. Therefore, in the presence of Lck, increased local concentration of substrates containing SH2 and SH3 binding sites such as CD3-⑀, driven by aggregation or relocalization, could be sufficient to induce their phosphorylation and cooperatively activate the signaling potential of Lck. Hence, CD3-⑀-ITAM would act as both an activator and a substrate for Lck. Activation of Lck in such a situation would be specific for and limited to that substrate. High affinity interaction between the SH2 domain of Lck and the phosphorylated substrate would impede release of the kinase, and any Lck that eventually escapes from the complex would presumably once again be subject to repression by its own SH3 domain. Such a mechanism, in which the substrate plays an active role in inducing its own phosphorylation by an otherwise inactive kinase, has obvious advantages where indiscriminate kinase activity can lead to disregulated signaling. A similar mechanism has been proposed to be involved in Src/p130 Cas-like protein Sin, and Abl/Cbl interactions (28, 30) . Therefore, it is conceivable that interaction of Lck with CD3-⑀ may have a positive effect on the TCR signaling events that are dependent on the recruitment of signaling proteins to the plasma membrane. In summary, the sequential and coordinated phosphorylation of Y 170 and Y 181 within CD3-⑀-ITAM provides to CD3-⑀ the potential to interact with multiple downstream effectors and signaling pathways.
